Cargando…
Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII)
AIM: To quantify the areas of burden experienced by patients requiring repeated intravitreal injections (IVI) in the management of exudative retinal diseases. METHODS: The validated Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections survey was administered to patients at fou...
Autores principales: | , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764643/ https://www.ncbi.nlm.nih.gov/pubmed/36794741 http://dx.doi.org/10.1136/bmjophth-2022-001188 |
_version_ | 1784853315555688448 |
---|---|
author | Wang, Rui McClard, Cynthia K Laswell, Stephen Mahmoudzadeh, Raziyeh Salabati, Mirataollah Ammar, Michael Vannavong, Jordyn Aziz, Aamir A Ewald, Amy Calvanese, Allison V Lehman, Erik B Fried, Sagit Windham, Victoria Strutt, Adriana Saroj, Namrata Khanani, Arshad Mohammad Eichenbaum, David A Regillo, Carl Wykoff, Charles Clifton |
author_facet | Wang, Rui McClard, Cynthia K Laswell, Stephen Mahmoudzadeh, Raziyeh Salabati, Mirataollah Ammar, Michael Vannavong, Jordyn Aziz, Aamir A Ewald, Amy Calvanese, Allison V Lehman, Erik B Fried, Sagit Windham, Victoria Strutt, Adriana Saroj, Namrata Khanani, Arshad Mohammad Eichenbaum, David A Regillo, Carl Wykoff, Charles Clifton |
author_sort | Wang, Rui |
collection | PubMed |
description | AIM: To quantify the areas of burden experienced by patients requiring repeated intravitreal injections (IVI) in the management of exudative retinal diseases. METHODS: The validated Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections survey was administered to patients at four retina clinical practices across four US states. The primary outcome measure was Treatment Burden Score (TBS), a single score assessing overall burden. RESULTS: Of 1416 (n=657 age-related macular degeneration; n=360 diabetic macular oedema/diabetic retinopathy; n=221 retinal vein occlusion; n=178 other/uncertain) patients, 55% were women with an average age of 70 years. Patients most frequently reported receiving IVI every 4–5 weeks (40%). The mean TBS was 16.1±9.2 (range 1–48; scale of 1–54), and the TBS was higher in patients with diabetic macular oedema and/or diabetic retinopathy (DMO/DR) (17.1) compared with those with age-related macular degeneration (15.5) or retinal venous occlusive (15.3) (p=0.028). Though the mean level of discomfort was quite low (1.86) (scale 0–6), 50% of patients reported experiencing side effects more than half of the visits. Patients having received fewer than 5 IVI reported higher mean anxiety levels before (p=0.026), during (p=0.050) and after (p=0.016) treatment compared with patients having received more than 50 IVI. After the procedure, 42% of patients reported restrictions from usual activities due to discomfort. Patients reported a high mean satisfaction rating of 5.46 (scale 0–6) with the care of their diseases. CONCLUSIONS: The mean TBS was moderate and highest among patients with DMO/DR. Patients with more total injections reported lower levels of discomfort and anxiety but higher disruption to daily life. Despite the challenges related to IVI, the overall satisfaction with treatment remained high. |
format | Online Article Text |
id | pubmed-9764643 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-97646432022-12-21 Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) Wang, Rui McClard, Cynthia K Laswell, Stephen Mahmoudzadeh, Raziyeh Salabati, Mirataollah Ammar, Michael Vannavong, Jordyn Aziz, Aamir A Ewald, Amy Calvanese, Allison V Lehman, Erik B Fried, Sagit Windham, Victoria Strutt, Adriana Saroj, Namrata Khanani, Arshad Mohammad Eichenbaum, David A Regillo, Carl Wykoff, Charles Clifton BMJ Open Ophthalmol Retina AIM: To quantify the areas of burden experienced by patients requiring repeated intravitreal injections (IVI) in the management of exudative retinal diseases. METHODS: The validated Questionnaire to Assess Life Impact of Treatment by Intravitreal Injections survey was administered to patients at four retina clinical practices across four US states. The primary outcome measure was Treatment Burden Score (TBS), a single score assessing overall burden. RESULTS: Of 1416 (n=657 age-related macular degeneration; n=360 diabetic macular oedema/diabetic retinopathy; n=221 retinal vein occlusion; n=178 other/uncertain) patients, 55% were women with an average age of 70 years. Patients most frequently reported receiving IVI every 4–5 weeks (40%). The mean TBS was 16.1±9.2 (range 1–48; scale of 1–54), and the TBS was higher in patients with diabetic macular oedema and/or diabetic retinopathy (DMO/DR) (17.1) compared with those with age-related macular degeneration (15.5) or retinal venous occlusive (15.3) (p=0.028). Though the mean level of discomfort was quite low (1.86) (scale 0–6), 50% of patients reported experiencing side effects more than half of the visits. Patients having received fewer than 5 IVI reported higher mean anxiety levels before (p=0.026), during (p=0.050) and after (p=0.016) treatment compared with patients having received more than 50 IVI. After the procedure, 42% of patients reported restrictions from usual activities due to discomfort. Patients reported a high mean satisfaction rating of 5.46 (scale 0–6) with the care of their diseases. CONCLUSIONS: The mean TBS was moderate and highest among patients with DMO/DR. Patients with more total injections reported lower levels of discomfort and anxiety but higher disruption to daily life. Despite the challenges related to IVI, the overall satisfaction with treatment remained high. BMJ Publishing Group 2022-12-19 /pmc/articles/PMC9764643/ /pubmed/36794741 http://dx.doi.org/10.1136/bmjophth-2022-001188 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Retina Wang, Rui McClard, Cynthia K Laswell, Stephen Mahmoudzadeh, Raziyeh Salabati, Mirataollah Ammar, Michael Vannavong, Jordyn Aziz, Aamir A Ewald, Amy Calvanese, Allison V Lehman, Erik B Fried, Sagit Windham, Victoria Strutt, Adriana Saroj, Namrata Khanani, Arshad Mohammad Eichenbaum, David A Regillo, Carl Wykoff, Charles Clifton Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) |
title | Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) |
title_full | Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) |
title_fullStr | Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) |
title_full_unstemmed | Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) |
title_short | Quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (QUALITII) |
title_sort | quantifying burden of intravitreal injections: questionnaire assessment of life impact of treatment by intravitreal injections (qualitii) |
topic | Retina |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764643/ https://www.ncbi.nlm.nih.gov/pubmed/36794741 http://dx.doi.org/10.1136/bmjophth-2022-001188 |
work_keys_str_mv | AT wangrui quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT mcclardcynthiak quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT laswellstephen quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT mahmoudzadehraziyeh quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT salabatimirataollah quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT ammarmichael quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT vannavongjordyn quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT azizaamira quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT ewaldamy quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT calvaneseallisonv quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT lehmanerikb quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT friedsagit quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT windhamvictoria quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT struttadriana quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT sarojnamrata quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT khananiarshadmohammad quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT eichenbaumdavida quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT regillocarl quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii AT wykoffcharlesclifton quantifyingburdenofintravitrealinjectionsquestionnaireassessmentoflifeimpactoftreatmentbyintravitrealinjectionsqualitii |